Morgans Keeps Their Hold Rating on Home Consortium Ltd (HMC)
Morgans analyst Liam Schofield maintained a Hold rating on Home Consortium Ltd (HMC – Research Report) today and set a price target of A$5.20.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Schofield is ranked #6161 out of 9472 analysts.
In addition to Morgans, Home Consortium Ltd also received a Hold from Morgan Stanley's Simon Chan in a report issued today. However, on the same day, J.P. Morgan maintained a Buy rating on Home Consortium Ltd (ASX: HMC).
Based on Home Consortium Ltd's latest earnings release for the quarter ending December 30, the company reported a quarterly revenue of A$135.5 million and a net profit of A$166.9 million. In comparison, last year the company earned a revenue of A$40.22 million and had a net profit of A$348.02 million
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HMC in relation to earlier this year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ASX Value Stock Picks Including Lynas Rare Earths For Estimated Growth
As the ASX200 flirts with record highs, investor sentiment in Australia is cautiously optimistic, buoyed by potential trade deals and corporate activities like mergers and acquisitions. In such a climate, identifying undervalued stocks becomes crucial for investors looking to capitalize on market opportunities; companies with strong fundamentals and growth potential can offer promising prospects even amidst fluctuating sector performances. Name Current Price Fair Value (Est) Discount (Est) Superloop (ASX:SLC) A$2.85 A$4.92 42.1% Ridley (ASX:RIC) A$2.86 A$5.64 49.3% Praemium (ASX:PPS) A$0.685 A$1.16 40.8% Polymetals Resources (ASX:POL) A$0.825 A$1.54 46.3% PointsBet Holdings (ASX:PBH) A$1.195 A$2.05 41.8% Nuix (ASX:NXL) A$2.35 A$4.04 41.8% Nanosonics (ASX:NAN) A$4.35 A$6.92 37.1% Fenix Resources (ASX:FEX) A$0.285 A$0.47 38.9% Charter Hall Group (ASX:CHC) A$19.35 A$33.88 42.9% Capricorn Metals (ASX:CMM) A$9.12 A$14.62 37.6% Click here to see the full list of 32 stocks from our Undervalued ASX Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Overview: Lynas Rare Earths Limited operates in the exploration, development, mining, extraction, and processing of rare earth minerals in Australia and Malaysia with a market capitalization of A$8.04 billion. Operations: The company generates revenue primarily from its rare earth operations, amounting to A$482.82 million. Estimated Discount To Fair Value: 36.5% Lynas Rare Earths is trading at A$8.6, significantly below its estimated fair value of A$13.55, suggesting it may be undervalued based on discounted cash flow analysis. Despite a decline in profit margins from 33.2% to 10.5%, the company is expected to experience substantial earnings growth of over 61% annually, with revenue projected to grow at 38% per year, outpacing the broader Australian market's growth expectations. Our growth report here indicates Lynas Rare Earths may be poised for an improving outlook. Unlock comprehensive insights into our analysis of Lynas Rare Earths stock in this financial health report. Overview: Nanosonics Limited is a global infection prevention company with a market cap of A$1.32 billion. Operations: The company's revenue is primarily derived from its Healthcare Equipment segment, totaling A$183.97 million. Estimated Discount To Fair Value: 37.1% Nanosonics, trading at A$4.35, is valued below its estimated fair value of A$6.92, highlighting potential undervaluation based on discounted cash flow analysis. Earnings have grown 14.3% annually over the past five years and are forecast to increase significantly by 24.3% per year, outpacing the Australian market's growth rate of 11.6%. However, its future return on equity is projected to be relatively low at 13.9% in three years' time. The growth report we've compiled suggests that Nanosonics' future prospects could be on the up. Get an in-depth perspective on Nanosonics' balance sheet by reading our health report here. Overview: Ridley Corporation Limited, with a market cap of A$1.05 billion, provides animal nutrition solutions in Australia through its subsidiaries. Operations: The company's revenue is derived from two main segments: Bulk Stockfeeds, contributing A$894.26 million, and Packaged/Ingredients, accounting for A$389.70 million. Estimated Discount To Fair Value: 49.3% Ridley, trading at A$2.86, is priced below its estimated fair value of A$5.64, indicating potential undervaluation based on discounted cash flow analysis. Recent equity and fixed-income offerings might impact shareholder value in the short term. While revenue is expected to grow robustly at 20.7% annually, earnings growth of 16.6% per year surpasses the Australian market average but remains moderate compared to significant benchmarks. The company's dividend history is unstable, and return on equity forecasts are modest at 14.4%. Our expertly prepared growth report on Ridley implies its future financial outlook may be stronger than recent results. Click to explore a detailed breakdown of our findings in Ridley's balance sheet health report. Navigate through the entire inventory of 32 Undervalued ASX Stocks Based On Cash Flows here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:LYC ASX:NAN and ASX:RIC. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Marimaca Copper Announces Closing of First Tranche of US$17.7 Million Non-Brokered Private Placement
Not for distribution to U.S. newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities law. VANCOUVER, British Columbia, June 11, 2025 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. ('Marimaca' or the 'Company') (TSX: MARI) (ASX: MC2) is pleased to announce the closing of the first tranche of the previously announced non-brokered private placement (the 'Private Placement'). Pursuant to the Private Placement, Assore International Holdings Limited ('AIH') and Ithaki Limited ('Ithaki') each subscribed for 2,250,000 common shares of the Company (the 'Shares') at a price of C$4.60 per Share for total gross proceeds to the Company of approximately C$20,700,000 ('Tranche 1'). An additional institutional investor together with its affiliates (the 'Additional Investor') will subscribe on the same terms as AIH and Ithaki for an additional 811,416 Shares ('Tranche 2') for total gross proceeds of C$3,732,514. Tranche 2 is expected to close on or around June 12th, 2025 and is subject to standard irrevocable commitments. AIH is a related party of the Company by virtue of its significant shareholding and contractual right to nominate a director to the Company's board. Additionally, Ithaki is a related party of the Company by virtue of holding more than 10% of the issued and outstanding Shares. The net proceeds from the Private Placement will be used for exploration, to advance the Company's flagship Marimaca Copper Project located in the Antofagasta Region of northern Chile and for general corporate purposes. The Shares issued pursuant to the Tranche 1 are, and the Shares to be issued pursuant to Tranche 2 will be, subject to a statutory hold period of four months and one day in accordance with applicable Canadian securities laws and are being issued pursuant to the ASX Listing Rule 10.11 waiver granted to Marimaca at the time of admission. Related Party Transaction Disclosure The participation by AIH and Ithaki, each of which is a 'related party' of the Company under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'), constitutes a 'related party transaction.' The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements under sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as neither the fair market value of the Shares issued to, nor the consideration paid by, such related parties exceeds 25% of the Company's market capitalization. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. Other Information In connection with the Private Placement, Greenstone Resources L.P. and certain of its affiliates have agreed to waive their respective option to participate pro rata in equity financings by the Company. In addition, in connection with the Private Placement, Mitsubishi has been offered the option to purchase Shares pro rata on the same terms as the Private Placement within 30 business days of the closing of the Private Placement. Mitsubishi's current ownership, prior to giving effect to the Private Placement, is approximately 4.6% based on public filings. About Marimaca Marimaca is a copper exploration and development company focused on its 100%-owned flagship Marimaca Copper Project and surrounding exploration properties located in Antofagasta Region, Chile. The Marimaca Copper Project hosts the Marimaca Oxide Deposit (the 'MOD'), an IOCG-type copper deposit. The Company is currently progressing the Marimaca Copper Project through the Definitive Feasibility Study led by Ausenco Chile Ltda. In parallel, the Company is exploring its extensive land package in the Antofagasta region, including the >15,000ha wholly-owned Sierra de Medina property block, located 25km from the MOD. This news release is authorized for release by the Board of Directors of Marimaca. Contact InformationFor further information, please visit or contact: Tavistock+44 (0) 207 920 3150Emily Moss / Ruairi Millarmarimaca@ Forward-Looking Statements This news release includes certain 'forward-looking statements' under applicable Canadian securities legislation, including statements related to the anticipated participation in the Tranche 2 of the Private Placement, the closing date of Tranche 2 of the Private Placement, advisory fees payable and the use of proceeds. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by Marimaca, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: risks related to share price and market conditions, the inherent risks involved in the mining, exploration and development of mineral properties, the uncertainties involved in interpreting drilling results and other geological data, fluctuating metal prices, the possibility of project delays or cost overruns or unanticipated excessive operating costs and expenses, uncertainties related to the necessity of financing, uncertainties relating to regulatory procedure and timing for permitting reviews, the availability of and costs of financing needed in the future. The intended use of the proceeds of the Private Placement by the Company might change if the board of directors of the Company determines that it would be in the best interests of the Company. Many of these risks and uncertainties and additional risk factors generally applicable to the Company are described in the Company's annual information form of the Company dated March 27, 2025 and other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements contained herein, whether as a result of new information or future events or otherwise, except as may be required by law. None of the TSX, ASX or the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.
Yahoo
7 hours ago
- Yahoo
Citi sees Gilead clinical holds as only ‘minor setback'
Citi analyst Geoff Meacham keeps a Buy rating on Gilead (GILD) with a $125 price target after the company announced a clinical hold on its Phase 2 WONDERS trials evaluating the combination of GS-1720 and GS-4182 for once-weekly oral HIV treatment. The hold was initiated due to safety concerns, specifically decreases in CD4+ T-cell and absolute lymphocyte counts observed in a subset of participants receiving the combination therapy, the analyst tells investors in a research note. Citi says the setback impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously anticipated in 2029 or 2030. The hold does not affect Gilead's other ongoing HIV programs, including lenacapavir development for both treatment and prevention including the monthly oral combinations, as no similar lymphocyte or CD4 effects have been observed in these studies, Citi points out. As such, the firm sees the holds as a 'minor setback' and continues to believe that lenacapavir in pre-exposure prophylaxis and expansion of several differentiated lenacapavir combos should offset potential Biktarvy 2028 Inflation Reduction Act negotiations. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue FDA placed clinical hold on Gilead HIV treatment trials of GS-1720 Gilead down 2% to $111.14 after FDA placed hold on some HIV trials Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
